Estimated reading time: 5 minutes Key Takeaways BioNTech and Bristol Myers forge a major partnership in oncology drug development. Shares of BioNTech surged over 20% following the announcement. The cutting-edge …
-
-
Estimated reading time: 6 minutes Key Takeaways The U.S. government plans to double steel import tariffs to 50% by 2025 Steel stocks have skyrocketed since the announcement Policy changes boost …
-
Estimated reading time: 5 minutes Key Takeaways Tariffs have significantly dented Campbell Soup’s 2025 profit outlook. Despite exceeding earnings estimates, escalating trade policies pose substantial challenges. The Snacks division remains …
-
Estimated reading time: 5 minutes Key Takeaways Meta aims to launch *AI-powered* automated ad creation by 2026. This initiative will streamline ad creation processes and significantly reduce resource requirements. AI-driven …
-
Estimated reading time: 5 minutes Key Takeaways Moderna’s new COVID-19 vaccine has gained approval from the FDA. Known as mRNA-1283 or Spikevax, it specifically targets the LP.8.1 variant. Shares of …
-
Estimated reading time: 6 minutes Key Takeaways Sanofi acquires Blueprint Medicines for $9.5 billion, marking a bold expansion into rare immunological diseases. The deal offers a 27% premium over Blueprint’s …
-
Estimated reading time: 5 minutes Key Takeaways The fragile trade truce between the US and China is under renewed stress. China accuses the US of actions that “seriously undermine” the …
-
Estimated reading time: 6 minutes Key Takeaways SAIC’s Q1 revenue grew by 2% year-over-year, indicating modest top-line expansion. Profits dipped by 12%, signalling rising operational costs and margin pressures. Negative …
-
Estimated reading time: 6 minutes Key Takeaways We see a dramatic surge in steel stocks following doubled tariffs. Major players like Cleveland-Cliffs and Nucor reported significant pre-market gains. Tariff policy …
-
Estimated reading time: 5 minutes Key Takeaways Sanofi has announced its intent to acquire Blueprint Medicines for $9.1 billion. This deal expands Sanofi’s presence in rare diseases and immunology. Blueprint’s …